The invention concerns the treatment of insulin-resistant disorders. In particular, the invention concerns the treatment of insulin-resistant disorders by administration of IL-17, such as IL-17A and/or IL-17F antagonists, such as anti-IL-17A and/or IL-17F and/or IL-17Rc antibodies, or antibody fragments.本發明係關於胰島素阻抗性疾病之治療。本發明特別關於藉由投與IL-17(諸如IL-17A及/或IL-17F)拮抗劑(諸如抗IL-17A及/或抗IL-17F及/或抗IL-17Rc抗體,或抗體片段)治療胰島素阻抗性疾病。